Pfizer First Comments on 3SBio’s PD-1/VEGF Bispecific

At Goldman Sachs' 46th Annual Global Healthcare Conference, Pfizer CEO Albert Bourla detailed the USD 1.2 billion upfront payment for 3SBio’s PD-1/VEGF bispecific SSGJ-707, calling it "a fabulous asset" with strong clinical data — though currently limited to China. Pfizer conducted weeks of on-site due diligence, visiting trial sites and interviewing investigators.

Bourla highlighted SSGJ-707’s strategic value, noting its standalone potential and synergy with Pfizer’s ADC pipeline. The total deal could reach USD 6 billion if successful. Pfizer’s 2024 BD budget is USD 10 billion to 15 billion, prioritising smaller deals.

Source:

https://mp.weixin.qq.com/s?__biz=MzAwNzMyNzQzNg==&mid=2650660821&idx=1&sn=5081b68f2ee0536ab3e9c1cebfeec640

Subscribe to our newsletter
A weekly newsletter curated for industry professionals. Join thousands of fellow subscribers for free
Subscribe for Free
Daily News
Evopoint Files for IPO After Completing RMB 700m Series E Financing​​
2025-07-01
Innovent Initiates First Phase III Trial of CLDN18.2 ADC for Pancreatic Cancer​​
2025-07-01
Innovent's Mazdutide Approved as First Global Dual-Target Weight Loss Drug
2025-07-01
​​Mabwell Licenses Long-Acting G-CSF to Qilu in Potential RMB 500m Deal​​
2025-07-01
Immvira Bioscience Files for Hong Kong IPO
2025-06-28
Latest Report
Global Drug Progress Report during April 2025
Details